Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2026

1 Monoclonal Antibody VEGF Inhibitors Market Overview
1.1 Product Definition
1.2 Monoclonal Antibody VEGF Inhibitors by Type
1.2.1 Global Monoclonal Antibody VEGF Inhibitors Market Value by Type: 2025 vs 2032
1.2.2 Ramucirumab
1.2.3 Bevacizumab
1.2.4 Ranibizumab
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Monoclonal Antibody VEGF Inhibitors by Application
1.3.1 Global Monoclonal Antibody VEGF Inhibitors Market Value by Application: 2025 vs 2032
1.3.2 Degenerative Eye Diseases
1.3.3 Cancer
1.3.4 Other
1.4 Global Monoclonal Antibody VEGF Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody VEGF Inhibitors Revenue 2021–2032
1.4.2 Global Monoclonal Antibody VEGF Inhibitors Sales 2021–2032
1.4.3 Global Monoclonal Antibody VEGF Inhibitors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Monoclonal Antibody VEGF Inhibitors Market Competition by Manufacturers
2.1 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Monoclonal Antibody VEGF Inhibitors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Monoclonal Antibody VEGF Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Monoclonal Antibody VEGF Inhibitors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody VEGF Inhibitors, Product Types and Applications
2.7 Global Key Manufacturers of Monoclonal Antibody VEGF Inhibitors, Date of Entry into the Industry
2.8 Global Monoclonal Antibody VEGF Inhibitors Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody VEGF Inhibitors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Monoclonal Antibody VEGF Inhibitors Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody VEGF Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody VEGF Inhibitors Market Scenario by Region
3.1 Global Monoclonal Antibody VEGF Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021–2032
3.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021–2026
3.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2027–2032
3.3 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2021–2032
3.3.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2021–2026
3.3.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2027–2032
3.4 North America Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021–2032)
3.4.3 North America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2021–2032)
3.5.3 Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody VEGF Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Region (2021–2032)
3.6.3 Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021–2032)
3.7.3 Latin America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021–2032)
4.1.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021–2026)
4.1.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2027–2032)
4.1.3 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021–2032)
4.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021–2032)
4.2.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021–2026)
4.2.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2027–2032)
4.2.3 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021–2032)
4.3 Global Monoclonal Antibody VEGF Inhibitors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021–2032)
5.1.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021–2026)
5.1.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2027–2032)
5.1.3 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021–2032)
5.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021–2032)
5.2.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021–2026)
5.2.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2027–2032)
5.2.3 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021–2032)
5.3 Global Monoclonal Antibody VEGF Inhibitors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Celltrion Healthcare
6.4.1 Celltrion Healthcare Company Information
6.4.2 Celltrion Healthcare Description and Business Overview
6.4.3 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.4.5 Celltrion Healthcare Recent Developments/Updates
6.5 Amgen
6.5.1 Amgen Company Information
6.5.2 Amgen Description and Business Overview
6.5.3 Amgen Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.5.5 Amgen Recent Developments/Updates
6.6 Amneal Pharmaceuticals,
6.6.1 Amneal Pharmaceuticals, Company Information
6.6.2 Amneal Pharmaceuticals, Description and Business Overview
6.6.3 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.6.5 Amneal Pharmaceuticals, Recent Developments/Updates
6.7 Coherus BioSciences
6.7.1 Coherus BioSciences Company Information
6.7.2 Coherus BioSciences Description and Business Overview
6.7.3 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.7.5 Coherus BioSciences Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Company Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Chia Tai Tianqing
6.9.1 Chia Tai Tianqing Company Information
6.9.2 Chia Tai Tianqing Description and Business Overview
6.9.3 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.9.5 Chia Tai Tianqing Recent Developments/Updates
6.10 Qilu Pharma
6.10.1 Qilu Pharma Company Information
6.10.2 Qilu Pharma Description and Business Overview
6.10.3 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.10.5 Qilu Pharma Recent Developments/Updates
6.11 Boan Biotech
6.11.1 Boan Biotech Company Information
6.11.2 Boan Biotech Description and Business Overview
6.11.3 Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.11.5 Boan Biotech Recent Developments/Updates
6.12 Jiangsu Hengrui Pharmaceuticals
6.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.12.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.12.3 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.13 SinoCellTech
6.13.1 SinoCellTech Company Information
6.13.2 SinoCellTech Description and Business Overview
6.13.3 SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.13.5 SinoCellTech Recent Developments/Updates
6.14 Innovent
6.14.1 Innovent Company Information
6.14.2 Innovent Description and Business Overview
6.14.3 Innovent Monoclonal Antibody VEGF Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio
6.14.5 Innovent Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody VEGF Inhibitors Industry Chain Analysis
7.2 Monoclonal Antibody VEGF Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody VEGF Inhibitors Production Mode & Process Analysis
7.4 Monoclonal Antibody VEGF Inhibitors Sales and Marketing
7.4.1 Monoclonal Antibody VEGF Inhibitors Sales Channels
7.4.2 Monoclonal Antibody VEGF Inhibitors Distributors
7.5 Monoclonal Antibody VEGF Inhibitors Customer Analysis
8 Monoclonal Antibody VEGF Inhibitors Market Dynamics
8.1 Monoclonal Antibody VEGF Inhibitors Industry Trends
8.2 Monoclonal Antibody VEGF Inhibitors Market Drivers
8.3 Monoclonal Antibody VEGF Inhibitors Market Challenges
8.4 Monoclonal Antibody VEGF Inhibitors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Monoclonal Antibody VEGF Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Monoclonal Antibody VEGF Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Monoclonal Antibody VEGF Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Monoclonal Antibody VEGF Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Monoclonal Antibody VEGF Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Monoclonal Antibody VEGF Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Monoclonal Antibody VEGF Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Monoclonal Antibody VEGF Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibody VEGF Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Monoclonal Antibody VEGF Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibody VEGF Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibody VEGF Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibody VEGF Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Monoclonal Antibody VEGF Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Monoclonal Antibody VEGF Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Monoclonal Antibody VEGF Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Monoclonal Antibody VEGF Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Monoclonal Antibody VEGF Inhibitors Product
Table 74. Roche Recent Developments/Updates
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Eli Lilly Monoclonal Antibody VEGF Inhibitors Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Pfizer Monoclonal Antibody VEGF Inhibitors Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Celltrion Healthcare Company Information
Table 86. Celltrion Healthcare Description and Business Overview
Table 87. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product
Table 89. Celltrion Healthcare Recent Developments/Updates
Table 90. Amgen Company Information
Table 91. Amgen Description and Business Overview
Table 92. Amgen Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Amgen Monoclonal Antibody VEGF Inhibitors Product
Table 94. Amgen Recent Developments/Updates
Table 95. Amneal Pharmaceuticals, Company Information
Table 96. Amneal Pharmaceuticals, Description and Business Overview
Table 97. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product
Table 99. Amneal Pharmaceuticals, Recent Developments/Updates
Table 100. Coherus BioSciences Company Information
Table 101. Coherus BioSciences Description and Business Overview
Table 102. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product
Table 104. Coherus BioSciences Recent Developments/Updates
Table 105. Novartis Company Information
Table 106. Novartis Description and Business Overview
Table 107. Novartis Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Novartis Monoclonal Antibody VEGF Inhibitors Product
Table 109. Novartis Recent Developments/Updates
Table 110. Chia Tai Tianqing Company Information
Table 111. Chia Tai Tianqing Description and Business Overview
Table 112. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product
Table 114. Chia Tai Tianqing Recent Developments/Updates
Table 115. Qilu Pharma Company Information
Table 116. Qilu Pharma Description and Business Overview
Table 117. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product
Table 119. Qilu Pharma Recent Developments/Updates
Table 120. Boan Biotech Company Information
Table 121. Boan Biotech Description and Business Overview
Table 122. Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Boan Biotech Monoclonal Antibody VEGF Inhibitors Product
Table 124. Boan Biotech Recent Developments/Updates
Table 125. Jiangsu Hengrui Pharmaceuticals Company Information
Table 126. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 127. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product
Table 129. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 130. SinoCellTech Company Information
Table 131. SinoCellTech Description and Business Overview
Table 132. SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. SinoCellTech Monoclonal Antibody VEGF Inhibitors Product
Table 134. SinoCellTech Recent Developments/Updates
Table 135. Innovent Company Information
Table 136. Innovent Description and Business Overview
Table 137. Innovent Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Innovent Monoclonal Antibody VEGF Inhibitors Product
Table 139. Innovent Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Monoclonal Antibody VEGF Inhibitors Distributors List
Table 143. Monoclonal Antibody VEGF Inhibitors Customers List
Table 144. Monoclonal Antibody VEGF Inhibitors Market Trends
Table 145. Monoclonal Antibody VEGF Inhibitors Market Drivers
Table 146. Monoclonal Antibody VEGF Inhibitors Market Challenges
Table 147. Monoclonal Antibody VEGF Inhibitors Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report


List of Figures
Figure 1. Product Picture of Monoclonal Antibody VEGF Inhibitors
Figure 2. Global Monoclonal Antibody VEGF Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Monoclonal Antibody VEGF Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Ramucirumab Product Picture
Figure 5. Bevacizumab Product Picture
Figure 6. Ranibizumab Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global Monoclonal Antibody VEGF Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 11. Global Monoclonal Antibody VEGF Inhibitors Market Share by Application: 2025 & 2032
Figure 12. Degenerative Eye Diseases
Figure 13. Cancer
Figure 14. Other
Figure 15. Global Monoclonal Antibody VEGF Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Monoclonal Antibody VEGF Inhibitors Market Size (US$ Million), 2021–2032
Figure 17. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units), 2021–2032
Figure 18. Global Monoclonal Antibody VEGF Inhibitors Average Price (US$/Unit), 2021–2032
Figure 19. Monoclonal Antibody VEGF Inhibitors Report Years Considered
Figure 20. Monoclonal Antibody VEGF Inhibitors Sales Share by Manufacturers in 2025
Figure 21. Global Monoclonal Antibody VEGF Inhibitors Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Monoclonal Antibody VEGF Inhibitors Players: Market Share by Revenue in Monoclonal Antibody VEGF Inhibitors in 2025
Figure 23. Monoclonal Antibody VEGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Monoclonal Antibody VEGF Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 26. North America Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 27. United States Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 30. Europe Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 31. Germany Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2021–2032)
Figure 38. China Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 46. Latin America Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 47. Mexico Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Monoclonal Antibody VEGF Inhibitors by Type (2021–2032)
Figure 57. Global Revenue Market Share of Monoclonal Antibody VEGF Inhibitors by Type (2021–2032)
Figure 58. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Monoclonal Antibody VEGF Inhibitors by Application (2021–2032)
Figure 60. Global Revenue Market Share of Monoclonal Antibody VEGF Inhibitors by Application (2021–2032)
Figure 61. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 62. Monoclonal Antibody VEGF Inhibitors Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit